New ‘Voices of MPN’ Initiative Unites, Connects and Supports Community Affected by Rare Blood Cancers: Myeloproliferative

  New ‘Voices of MPN’ Initiative Unites, Connects and Supports Community
  Affected by Rare Blood Cancers: Myeloproliferative Neoplasms (MPNs)

  *In Connection with Blood Cancer Awareness Month in September, Incyte
    Launches Community Awareness Program
  *September 12 Designated as Inaugural MPN Awareness Day

Business Wire

WILMINGTON, Del. -- September 3, 2013

September is Blood Cancer Awareness Month, and it is estimated that nearly
300,000 people in the United States are living with myeloproliferative
neoplasms (MPNs)^1, a group of closely related blood cancers that includes
myelofibrosis, polycythemia vera and essential thrombocythemia^2. People
impacted by chronic, rare conditions like MPNs may lack access to the
resources they need. Voices of MPN™, a new initiative developed by Incyte
Corporation, builds upon an idea originated by advocacy groups in the MPN
community, who believe that raising the voices of those with MPNs will shine a
light on these rare diseases and encourage unity, connection and support for
people affected by MPNs.

To raise awareness of these rare diseases, the MPN Coalition, a group of seven
patient organizations dedicated to providing support to people living with
these blood cancers, has designated September 12, 2013,as MPN Awareness Day.

“The needs of people living with rare diseases like MPNs can often go unheard.
But when we all join together – individuals, caregivers, advocates and health
care professionals – our voices are stronger,” stated Antje Hjerpe, MPN
Education Foundation.

The Voices of MPN website links people to disease information, educational
programs and community activities, while inviting them to share their stories.
A portion of the site is dedicated to recognizing individuals who have made a
significant impact on the MPN community. Voices of MPN Facebook, YouTube and
Pinterest pages invite people to learn more about MPNs and help spread
awareness through social media sharing.

“Incyte is committed to making a difference in the lives of patients,” stated
Paul A. Friedman, M.D., President and Chief Executive Officer, Incyte
Corporation. “By joining with others in the MPN community, our goal is to
increase awareness of MPNs and, through the Voices of MPN program, help people
living with MPNs make important connections within the community.”

Call for Nominees – MPN Heroes

The Voices of MPN website includes information on how to participate in the
MPN Heroes^TM recognition program, sponsored by Incyte and in collaboration
with CURE Media Group, publishers of CURE magazine. MPN Heroes is a program to
recognize individuals and organizations who have provided health care above
and beyond the standard of care, demonstrated outstanding commitment, provided
leadership to the community, or advanced science for MPNs. Nomination
instructions are available at www.MPNHeroes.com, and nomination forms will be
accepted until October 18, 2013. An independent judging panel will select MPN
Heroes for recognition under two categories: Commitment to the individual; and
commitment to the broader MPN community. Those recognized for commitment to
the individual will receive a plaque to recognize their achievement, and those
recognized for commitment to the broader MPN community will be asked to
designate an organization engaged in MPN activities to receive a $25,000
charitable donation.

For those who want to informally recognize a person who has touched the lives
of those impacted by MPNs, there is also the Wall of Voices, a virtual wall of
recognition where individuals can submit pictures and a few lines of testimony
about an individual or organization that has made a difference. Incyte will
donate $5 to the MPN Research Foundation, a 501(c)3 charity, for each posting
on the Wall of Voices. Upon completion of the posting, individuals will be
given the option to register for MPN updates and resources, including ribbons
and bracelets.

“The MPN Research Foundation is intensely focused on meeting the needs of
patients by supporting innovative MPN research in pursuit of new treatments
and eventually a cure for these rare blood cancers,” stated Barbara Vanhusen,
MPN Research Foundation. “Much progress has been made since we awarded our
first research grant in 2000, at a time when MPNs were not well understood by
the medical community, were largely ignored by the scientific community, and
had very limited treatment options. Today, it is gratifying to see so many new
alliances and programs in place and evolving to better serve the needs of
patients and their families.”

About Myeloproliferative Neoplasms (MPNs)

Myeloproliferative neoplasms (MPNs) are a closely related group of blood
cancers in which the bone marrow cells that produce the body's blood cells
develop and function abnormally.^2 The three main myeloproliferative neoplasms
are myelofibrosis, polycythemia vera, essential thrombocythemia.^2 MPNs are
progressive blood cancers that can strike anyone at any age. Estimates of the
prevalence of MPNs vary, but analysis of claims data suggests there may be as
many as 300,000 people in the U.S. living with MPNs^1. Although there is
currently not a cure for MPNs, the discovery of a gene marker, JAK2, in 2005
has led to the development of more effective, targeted therapies^2. Several
treatment options are available, including one new drug specifically for
myelofibrosis that was approved in 2012.^3

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company
focused on the discovery, development and commercialization of proprietary
small molecule drugs for oncology and inflammation. For additional information
on Incyte, please visit the Company's website at www.incyte.com.

References

^1 “Prevalence,” MPN Research Foundation,
http://www.mpnresearchfoundation.org/Prevalence
^2 “Learning About MPNs - PV, ET, PMF” MPN Research Foundation, 
http://www.mpnresearchfoundation.org/Overview-Page
^3 “Understanding MPNs,” MPN Advocacy & Education International,
http://mpnadvocacy.com/understanding-mpns/

Contact:

Incyte Corporation
Pamela M. Murphy, 302-498-6944
Vice President, Investor Relations & Corporate Communications
or
Sam Brown Inc.
Mariesa Kemble, 608-850-4745 (Media)
mariesak@sambrown.com
 
Press spacebar to pause and continue. Press esc to stop.